Literature DB >> 7402308

The role of D-1 and D-2 receptors.

M Schachter, P Bédard, A G Debono, P Jenner, C D Marsden, P Price, J D Parkes, J Keenan, B Smith, J Rosenthaler, R Horowski, R Dorow.   

Abstract

Dopamine receptors in intracerebral motor and endocrine systems have been divided into two main types, D-1 and D-2, dependent on the presence or absence of adenylate cyclase linkage. Here we have investigated a number of dopamine agonist and antagonist drugs in man that have different actions on D-1 and D-2 receptors in animals. Motor and endocrine effects in parkinsonian subjects seem to depend on drug interaction with D-2, but not D-1, receptors. These results may have important implications for the design of anti-parkinsonian and antipsychotic agents.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7402308     DOI: 10.1038/286157a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  23 in total

1.  Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission.

Authors:  R T Fremeau; G E Duncan; M G Fornaretto; A Dearry; J A Gingrich; G R Breese; M G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

Review 2.  A history of dopamine agonists. From the physiology and pharmacology of dopamine to therapies for prolactinomas and Parkinson's disease - a subjective view.

Authors:  R Horowski
Journal:  J Neural Transm (Vienna)       Date:  2006-08-10       Impact factor: 3.575

Review 3.  Pharmacological Agents Affecting Emesis : A Review (Part II).

Authors:  F Mitchelson
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

4.  Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.

Authors:  P M Beart; C J Cook; M Cincotta; D J de Vries; P Tepper; D Dijkstra; A S Horn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

5.  Neuroleptic malignant syndrome due to sulpiride.

Authors:  K Kashihara; K Ishida
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-08       Impact factor: 10.154

Review 6.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

7.  Turning behavior in rats with unilateral lesions of the subthalamic nucleus: synergism between D1 and D2 receptors.

Authors:  M G Murer; V Sinay; J H Pazo
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 8.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

Review 9.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

10.  A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.

Authors:  N Quinn; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.